Key result
In a h9c2 model of doxorubicin-induced cardiotoxicity, pretreatment with resveratrol for 24 hours significantly improved cell survival compared to dexrazoxane and carvedilol (p < 0.05).
Why the study?
Dexrazoxane is the only approved therapy to prevent anthracycline-induced cardiotoxicity but carries safety concerns and dose restrictions, creating a need for new prophylactic strategies.
Does resveratrol improve cell survival compared to dexrazoxane and carvedilol in a h9c2 model of doxorubicin-induced cardiotoxicity?
Population
Differentiated h9c2 cardiomyoblasts
Comparison
Resveratrol vs dexrazoxane vs carvedilol prior to doxorubicin treatment
Design
In vitro drug screening study
Authors
Loading...
Resveratrol merits further preclinical study in doxorubicin models; hypothesis-generating and should not yet change clinical practice.
Does resveratrol improve cell survival compared to dexrazoxane and carvedilol in a h9c2 model of doxorubicin-induced cardiotoxicity?
p-value: p=< 0.05
In an in vitro h9c2 cardiomyoblast model, resveratrol pretreatment significantly improved cell survival against doxorubicin-induced cardiotoxicity compared to dexrazoxane and carvedilol.
Monahan et al. (2021) studied Doxorubicin-induced cardiotoxicity. Resveratrol vs. Dexrazoxane and carvedilol was evaluated on Cell survival (p=< 0.05). In a h9c2 model of doxorubicin-induced cardiotoxicity, pretreatment with resveratrol for 24 hours significantly improved cell survival compared to dexrazoxane and carvedilol (p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: